Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

TBPH Relative to the S&P 500

TBPH Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Theravance Biopharma, Inc. (NASD:TBPH) seasonal charts above shows that a Buy Date of August 27 and a Sell Date of December 26 has resulted in a geometric average return of 10.94% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 20.82% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

To download TBPH seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: TBPH